Medications for Blastic Plasmacytoid Dendritic Cell Neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm  (BPDCN) is a rare cancer which is a subtype of acute myeloid leukemia (AML). BPDCN develops when an immature (blastic) immune cell called the plasmacytoid dendritic cell becomes malignant.

The malignant blastic plasmacytoid dendritic cells infiltrate skin, bone marrow, central nervous system (CNS) and other tissues.  The condition usually presents as skin lesions but can also present with swollen lymph nodes, enlarged liver and spleen, central nervous system dysfunction and other tissues affected by the BPDCN infiltrate. Some patients presentation is with bone marrow involvement with a decrease in red and white blood cells, and platelet counts.